Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials

Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis

(2016) William N Whiteley et al.   LANCET NEUROLOGY

Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial

(2016) Eivind Berge et al.   LANCET NEUROLOGY

Restriction of therapy mainly explains lower thrombolysis rates in reduced stroke service levels

(2016) Christoph Gumbinger et al.   NEUROLOGY

Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes

(2016) Kennedy R. Lees et al.   STROKE

Changes in European Label and Guideline Adherence After Updated Recommendations for Stroke Thrombolysis

(2015) Nadim Anani et al.  

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke

(2015) Bart M. Demaerschalk et al.   STROKE

Changes in European Label and Guideline Adherence After Updated Recommendations for Stroke Thrombolysis

(2015) Nadim Anani et al.   Circulation-Cardiovascular Quality and Outcomes

Details of a Prospective Protocol for a Collaborative Meta-Analysis of Individual Participant Data from all Randomized Trials of Intravenous rt-PA vs. Control: Statistical Analysis Plan for the Stroke Thrombolysis Trialists' Collaborative Meta-Analysis

(2013)   International Journal of Stroke

Guidelines for the Intravenous Application of Recombinant Tissue-type Plasminogen Activator (Alteplase), the Second Edition, October 2012: A Guideline From the Japan Stroke Society

(2013) Kazuo Minematsu et al.   Journal of Stroke & Cerebrovascular Diseases

Effect Size Measures and Their Relationships in Stroke Studies

(2013) Volker W. Rahlfs et al.   STROKE

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

(2012)   LANCET

Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial

(2008) Stephen M Davis et al.   LANCET NEUROLOGY

Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke

(2008) Werner Hacke et al.   NEW ENGLAND JOURNAL OF MEDICINE